Please assess the completion status of the following clinical trial:

Trial Title: Study of Cilofexor in Adults With Primary Sclerosing Cholangitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of large duct PSC~* Liver biopsy at screening that is deemed acceptable for interpretation and demonstrates stage F0 - F3 fibrosis in the opinion of the central reader~* Individual has the following laboratory parameters at the screening visit, as determined by the central laboratory:~  * Platelet count ≥ 150,000/mm\^3~ * Estimated glomerular filtration rate (eGFR) ≥ 30 milliliter/minute (mL/min), as calculated by the Cockcroft-Gault equation~ * Alanine transaminase (ALT) ≤ 8 x upper limit of the normal range (ULN)~ * Total bilirubin \< 2 mg/dL, unless the individual is known to have Gilbert's syndrome or hemolytic anemia~ * International normalized ratio (INR) ≤ 1.4, unless due to therapeutic anticoagulation~ * Negative anti-mitochondrial antibody~Key Exclusion Criteria:~* Current or prior history of any of the following:~  * Cirrhosis~ * Liver transplantation~ * Cholangiocarcinoma or hepatocellular carcinoma (HCC)~ * Ascending cholangitis within 30 days of screening~* Presence of a percutaneous drain or biliary stent~* Other causes of liver disease~* Current or prior history of unstable cardiovascular disease~* Current moderate to severe inflammatory bowel disease (IBD) (including ulcerative colitis, Crohn's disease, and indeterminate colitis)~Note: Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cilofexor 100 mg (Blinded Phase) (Type: EXPERIMENTAL): Participants received cilofexor 100 mg tablet, orally, once daily for up to 100.3 weeks.
- Placebo (Blinded Phase) (Type: PLACEBO_COMPARATOR): Participants received placebo to match cilofexor 100 mg tablet, orally, once daily for up to 98.1 weeks.
- Cilofexor From Cilofexor 100 mg (OLE Phase) (Type: EXPERIMENTAL): Participants who received cilofexor in blinded phase and had entered the open-label extension (OLE) phase received open-label cilofexor 100 mg tablet, orally, once daily for up to 44.7 weeks.
- Cilofexor From Placebo (OLE Phase) (Type: EXPERIMENTAL): Participants who received placebo in blinded phase and had entered the OLE phase received open-label cilofexor 100 mg tablet, orally, once daily for up to 45.0 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).